Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study
about
The Human Experience with Intravenous LevodopaTherapy for Parkinson's disease: what is in the pipeline?Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?An updated meta-analysis of amantadine for treating dyskinesia in Parkinson's disease.NMDA receptors in clinical neurology: excitatory times ahead.Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbersCurrent approaches to the treatment of Parkinson's diseaseM4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced DyskinesiaAmantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)Impact of Oral Fast Release Amantadine on Movement Performance in Patients with Parkinson's DiseaseLevodopa-induced dyskinesias in Parkinson's disease: emerging treatmentsADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.Investigational agents in the treatment of Parkinson's disease: focus on safinamide.MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism.Understanding and prevention of "therapy-" induced dyskinesias.Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptorsRandomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis.Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease.Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.Safinamide: an add-on treatment for managing Parkinson's disease.Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson's Disease: An Open-Label, Pragmatic Trial.Cardinal Motor Features of Parkinson's Disease Coexist with Peak-Dose Choreic-Type Drug-Induced Dyskinesia.
P2860
Q26771516-2B4BF148-4593-4DB5-BD55-FA7ED2B49017Q26991826-2D2A65BC-E2BE-4C69-9AD3-4858AEE0E56BQ27021464-90A90A93-5937-4924-AC2C-25107BC64E92Q36376607-9E2F6DB6-2B72-4A2C-85B4-040D1EAD8FEBQ36660216-254CEFDA-7144-4B12-BFA0-39AEF409D0E6Q36799584-8470BA2F-13CC-426B-984F-018E1E72C26BQ36876438-8CFE5A12-EBBD-4396-9D9D-7BBEBC1B900DQ36892615-DCC2CA3B-C1F9-410E-8E00-AF135622B06FQ37257345-716C5D0D-32D7-4E6D-9294-B291829F59BAQ37666696-0F9369AA-016C-4522-A556-868B8820145CQ38156760-B94CF431-74CB-4629-8CD5-1775133321EBQ38375701-2CD02351-334D-46A7-A041-D539F22C63ABQ38836062-B3454E50-5C4A-4662-9030-FB74644987B1Q39906818-5087CBF6-FF19-46DC-AFBE-4C96D76CC4BCQ42052125-304CC2E9-6DBF-4CE7-B2A6-45A7A1DF03DDQ42121362-4FE53BE6-1421-49F0-AA63-415DB0F60E77Q46641045-315D90CE-609C-4647-B845-89100A848744Q49926091-9C971861-A99B-46BB-A313-996E0BE8B9D7Q52562719-B192B19F-837E-471E-9E22-1D315711132FQ52658932-7A4DE447-AE05-4816-B0C0-BF05038F92BAQ52804779-26AD2E72-C039-4F16-8409-5602A92FAB67Q55312669-50FAB7FA-D810-4DDD-A4DA-9B5A5D4539A9Q55431534-F171AE29-46C4-4A48-9BE5-CF2FDB51E041
P2860
Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study
@ast
Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study
@en
Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study
@nl
type
label
Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study
@ast
Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study
@en
Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study
@nl
prefLabel
Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study
@ast
Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study
@en
Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study
@nl
P2093
P1433
P1476
Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study
@en
P2093
P304
P356
10.1001/ARCHNEUR.56.11.1383
P407
P577
1999-11-01T00:00:00Z